COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02326740
Recruitment Status : Terminated
First Posted : December 29, 2014
Last Update Posted : April 27, 2016
Information provided by (Responsible Party):

Brief Summary:
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).

Condition or disease Intervention/treatment Phase
Pyoderma Gangrenosum Drug: gevokizumab Drug: Placebo Drug: gevokizumab open-label Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Study Start Date : December 2014
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: gevokizumab
Solution for subcutaneous injection (Part 1, Group B)
Drug: gevokizumab
Placebo Comparator: Placebo
Solution for subcutaneous injection (Part 1, Group A)
Drug: Placebo
Experimental: gevokizumab open-label
Solution for subcutaneous injection (Part 2, Open-label)
Drug: gevokizumab open-label

Primary Outcome Measures :
  1. The proportion of subjects at Day 126 with complete closure of the PG target ulcer confirmed 2 weeks later (at Day 140) and without the need for rescue treatment [ Time Frame: Day 126 ]

Secondary Outcome Measures :
  1. The proportions of subjects at Day 126 with a reduction in the target ulcer area of ≥ 75% or ≥ 90% from baseline. [ Time Frame: Day 126 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A clinical diagnosis of classic pyoderma gangrenosum
  • An active pyoderma gangrenosum ulcer
  • Contraceptive measures adequate to prevent pregnancy during the study

Exclusion Criteria:

  • Clinical evidence of acutely infected pyoderma gangrenosum
  • History of allergic or anaphylactic reactions to monoclonal antibodies
  • History of recurrent or chronic systemic infections
  • Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02326740

Layout table for location information
United States, California
Oceanside, California, United States
United States, Florida
Tampa, Florida, United States
United States, Georgia
Macon, Georgia, United States
United States, Missouri
St. Louis, Missouri, United States
United States, Nevada
Henderson, Nevada, United States
United States, New York
Bronx, New York, United States
Rochester, New York, United States
Australia, Queensland
Benowa, Queensland, Australia
Woolloongabba, Queensland, Australia
Australia, Victoria
Parkville, Victoria, Australia
Fremantle, Australia
St. Leonards, Australia
Sydney, Australia
Westmead, Australia
Canada, Ontario
Markham, Ontario, Canada
Richmond Hill, Ontario, Canada
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: XOMA (US) LLC Identifier: NCT02326740    
Other Study ID Numbers: X052173
First Posted: December 29, 2014    Key Record Dates
Last Update Posted: April 27, 2016
Last Verified: April 2016
Keywords provided by XOMA (US) LLC:
Pyoderma Gangrenosum
Classic Pyoderma Gangrenosum
Additional relevant MeSH terms:
Layout table for MeSH terms
Pyoderma Gangrenosum
Skin Diseases
Skin Diseases, Vascular
Skin Ulcer